Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Edesa Biotech › CEO received an award of 19K EDSA shares Insider trades
Why it stands out Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Nov 4, 2026
Reporting period Not applicable
Filed with the SEC Nov 5, 2026 CEO Grant / award
Context Classification grant award
Code A — grant or award
Planned / mechanical clue Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001171843-26-007187
Filed / recorded
Nov 5, 2026, 10:01 PM UTC
Added to OQRO Nov 5, 2026, 10:05 PM UTC
Data quality Verified: identifiers matched exactly
Issuer Edesa Biotech, Inc.
Reporting person Pardeep Nijhawan
Relationship Director, Officer, 10% owner
Officer title Chief Executive Officer
Table Non-derivative (Table I)
Transaction date Nov 4, 2026
Acquired / disposed Acquired (A)
Shares owned after 952,272
Footnotes from the filing Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
Around the same time Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Oct 23, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On October 23, 2026, the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board, approved increases in the annual base salaries of Dr. Pardeep Nijhawan, the Company’s Chief Executive Officer, from $357,696 to $657,423, Dr. Michael Brooks, the Company’s President, from $335,340 to $591,681, and Peter Weiler, the Company’s Chief…” Nov 4, 2026 5% stake Millennium Management LLC reported a passive stake (13G) of 8.7% What came next Nov 8, 2026 Company filing · Form 8-K · Material agreement, Agreement ended Signed an important agreement, and ended an important agreement (and 1 more item) Nov 12, 2026 5% stake Adage Capital Management, L.P. reported a passive stake (13G) of 7.8% Nov 16, 2026 5% stake Sirenia Capital Management LP reported a passive stake (13G) of 9.9% Nov 16, 2026 5% stake StemPoint Capital LP reported a passive stake (13G) of 9.9% Nov 16, 2026 5% stake Rubric Capital Management LP reported a passive stake (13G) of 4.6% Nov 16, 2026 5% stake Boxer Capital Management, LLC reported a passive stake (13G) of 6.9% Nov 16, 2026 5% stake Perceptive Advisors LLC reported a passive stake (13G) of 4.2%